1-3 of 3
James Tsai
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Mixed Type 1 and Type 2 Kinase Inhibitor That Overrides FLT3 F691 and D835 Resistance Mutations

Jack Lin, PhD, Ying Zhang, PhD, Bernice Matusow, Adam Mumy, Garson Tsang, Jiazhong Zhang, PhD, Hannah Powers, Wayne Spevak, PhD, Paul Severson, PhD, James Tsai, Gideon Bollag, PhD, Chao Zhang, PhD
Journal: Blood
Blood (2016) 128 (22): 1074.
https://doi.org/10.1182/blood.V128.22.1074.1074
Published: 2016
Journal Articles

The Combination of PLX3397, a Selective FLT3-ITD Inhibitor, and Decitabine, a Hypomethylating Agent, Demonstrates Benefit in AML Cell Lines in Vitro and in Vivo

James Tsai, Elizabeth A Burton, PhD, Gaston Habets, PhD, Brian West, PhD, Paul Lin, MD, Henry Hsu, MD, Chao Zhang, PhD, Gideon Bollag, PhD
Journal: Blood
Blood (2014) 124 (21): 3743.
https://doi.org/10.1182/blood.V124.21.3743.3743
Published: 2014
Journal Articles

Postoperative Venous Thromboembolism Associated With Surgical Admissions In Veterans Health Administration Hospitals, 2005–2010

Richard E Nelson, PhD, Scott D Grosse, PhD, Junji Lin, PhD, Scott DuVall, PhD, Olga Patterson, PhD, James Tsai, M.D., M.P.H., Nimia Reyes, MD, MPH, Norman J Waitzman, PhD
Journal: Blood
Blood (2013) 122 (21): 1708.
https://doi.org/10.1182/blood.V122.21.1708.1708
Published: 2013